Answer
Gazyvaro (obinutuzumab) is contraindicated in patients with hypersensitivity to obinutuzumab or any of the excipients listed in section 6.1 of its product information.
Sources for this answer
- Gazyvaro 1,000 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.3 Contraindications · Version 20Document updated
Sources checked